ZhuZhou QianJin Pharmaceutical Co., Ltd. (600479.SS) researches, develops, produces and sells Chinese patent medicines, chemical medicines and feminine hygiene products in China; engages in the wholesale and retail of pharmaceuticals; and operates ancillary businesses including sales of health care products, cosmetics, disinfectants, daily necessities and equity investments. Core products encompass gynecological Qianjin tablets and capsules for women's health; blood supplementation pills and granules; valsartan capsules and enalapril maleate tablets for cardiovascular treatment; difenidol hydrochloride tablets; silybin glucamine tablets; entecavir dispersible tablets for antiviral use; finasteride tablets; ammonium benzenesulfonate tablets; and specialized gynecological wipes, spanning gynecology, pediatrics, circulatory, endocrine, digestive, nervous system and other therapeutic categories in tablets, granules and capsules. Founded in 1966 as the predecessor Zhuzhou Pharmaceutical Company's Proprietary Chinese Medicine Processing Plant, it underwent shareholding reform in 1993, listed on the Shanghai Stock Exchange in 2004 and maintains headquarters at No. 801 Zhuzhou Avenue, Tianyuan District, Zhuzhou, Hunan province, China, with primary operations across the country. In October 2025, the company completes the acquisition of 28.92% equity in Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. and 68% equity in Hunan Qianjin Xieli Pharmaceutical Co., Ltd. for approximately CNY 620 million in cash and shares to bolster its pharmaceutical portfolio.